227 results about "Aqueous humor" patented technology

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Described here are systems and methods for accessing Schlemm's canal and for delivering an ocular device or fluid composition therein. The ocular devices may maintain the patency of Schlemm's canal without substantially interfering with transmural fluid flow across the canal. The fluid composition may be a viscoelastic fluid that is delivered into the canal to facilitate drainage of aqueous humor by disrupting the canal and surrounding trabeculocanalicular tissues. Tools for disrupting these tissues and minimally invasive methods for treating medical conditions associated with elevated intraocular pressure, including glaucoma, are also described.

Described here are systems and methods for accessing Schlemm's canal and for delivering an ocular device, tool, or fluid composition therein. The ocular devices may maintain the patency of Schlemm's canal without substantially interfering with transmural fluid flow across the canal. The fluid composition may be a viscoelastic fluid that is delivered into the canal to facilitate drainage of aqueous humor by disrupting the canal and surrounding trabeculocanalicular tissues. Some systems described here may be configured to cut or tear the trabecular meshwork with the body of an elongate member located within Schlemm's canal. Other tools for disrupting these tissues and minimally invasive methods for treating medical conditions associated with elevated intraocular pressure, including glaucoma, are also described.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Described here are systems and methods for accessing Schlemm's canal and for delivering an ocular device or fluid composition therein. The ocular devices may maintain the patency of Schlemm's canal without substantially interfering with transmural fluid flow across the canal. The fluid composition may be a viscoelastic fluid that is delivered into the canal to facilitate drainage of aqueous humor by disrupting the canal and surrounding trabeculocanalicular tissues. Tools for disrupting these tissues and minimally invasive methods for treating medical conditions associated with elevated intraocular pressure, including glaucoma, are also described.

The invention discloses a pupil reflex real-time detection and analysis system, and belongs to the technical field of pupil detection. According to the method, pupil reflex of a single eye or two eyes is continuously detected in real time, interference factors such as blinking and eyelash shielding are filtered out, pupil image deformation caused by eye movement is corrected, and optical influences of cornea and aqueous humor are corrected; meanwhile, various stimulation sources and various stimulation modes are provided, and more stimulation sources can be expanded; corresponding detection programs are set according to different diseases, and reflex conditions of pupils are detected in a targeted mode; for examination results, multiple categories of pupil reflex parameters are defined, feature parameters are selected to establish a feature database of normal people and people with different diseases, and an intelligent classification method is provided for clinical diagnosis reference; according to the invention, the measurement precision is improved, the application field is expanded, and the clinical practicability is improved.

The utility model discloses an aqueous humor quantitative collecting device capable of accurately controlling pressure, which is characterized in that a limiting device is arranged on an adjusting device; the control button is slidably arranged on the adjusting device in a sleeving mode and can rotate to a locking working position or a starting working position relative to the adjusting device. The piston assembly penetrates through the limiting device and the adjusting device and is fixedly installed on the control button. A plurality of scale marks are arranged on the outer wall of the suction cylinder, the suction cylinder is fixed to the adjusting device, and the suction cylinder is arranged outside the limiting device and the piston assembly in a sleeving mode; the liquid collecting assembly is installed at the end, away from the adjusting device, of the suction barrel and communicates with the suction barrel. By using the device, intraoperative side injury caused by movement of eyeballs of a patient in an operation can be effectively avoided, meanwhile, loss of intraocular fluid sample amount collected by an injector is avoided, the volume of the sampled intraocular fluid can be accurately controlled, the intraocular pressure level can be reduced, the operation process is convenient and rapid, and pain of the patient is obviously relieved.

Described here are systems and methods for accessing Schlemm's canal and for delivering an ocular device or fluid composition therein. The ocular devices may maintain the patency of Schlemm's canal without substantially interfering with transmural fluid flow across the canal. The fluid composition may be a viscoelastic fluid that is delivered into the canal to facilitate drainage of aqueous humor by disrupting the canal and surrounding trabeculocanalicular tissues. Tools for disrupting these tissues and minimally invasive methods for treating medical conditions associated with elevated intraocular pressure, including glaucoma, are also described.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

A surgical instrument (40, 40A) for performing a goniotomy procedure includes a hand grip (44, 44A) having an elongated configuration with proximal and distal ends. The instrument (40, 40A) includes a tip (52, 52A) connected to the distal end (48, 48A) of the hand grip (44, 44A) which has a cutting means for creating a trabecular cleavage plane resulting in a remaining trabecular leaflet directly below Schwalbe's line in an eye to enhance drainage of aqueous humor from the eye. In one form, the cutting means includes a pair of sloping, arcuate cutting surfaces (70, 70A) that join to define an arcuate cutting edge (74, 74A).

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

A glaucoma aqueous humor drainage tube implantation and injection device, which relates to the field of ophthalmology. The glaucoma aqueous humor drainage tube implantation and injection device comprises a protective housing (1), wherein an adjustable lower housing (8) is slidably connected to an inner wall of the protective housing (1), a fixing post (3) is fixedly connected to a surface of the protective housing (1), a left opening and clamping plate (4) and a right opening and clamping plate (5) are each rotationally connected to a surface of the fixing post (3), contact plates (6) are fixedly connected to both the bottom ends of the left opening and clamping plate (4) and the right opening and clamping plate (5), adhesive stickers (7) are fixedly connected to both the lower surfaces of the pair of contact plates (6), an adjustable rotating cylinder (2) is rotationally connected to the inner wall of the protective housing (1), and an adjustable pressure-reducing mechanism (9) is in threaded connection with an inner wall of the adjustable rotating cylinder (2). The adhesive stickers (7) are provided to adhere to the skin of a human body to provide support, so as to prevent eyelids of a patient from resetting due to fatigue during surgery; by means of providing the left opening and clamping plate (4) and the right opening and clamping plate (5), balanced support is maintained; by providing the protective housing (1), the movement of the adjustable lower housing (8) is guided and positioned; the adjustable pressure-reducing mechanism (9) is provided such that the eyelids of the patient are supported and tensioned during surgery and remain stable; and the functions of needling and of aqueous humor flow guiding are integrated, so as to avoid frequent replacement of a device during surgery.

An implant and method for regulating the intraocular pressure of an eye is described. The implant is disposed in Schlemm's canal of an eye through ab-externo or ab-interno canaloplasty. Once inserted, the implant monitors the intraocular pressure of an eye with a pressure sensor and provides regulated current to electrodes within the implant to perform electrolysis. Electrolysis causes a release of gas from the eye and a reduction in the volume of aqueous humor to decrease intraocular pressure. The degree of electrolysis and reduction of intraocular pressure is regulated by a platform that includes monitoring by a pressure sensor, safety controls, and remote access.

The embodiment of the invention discloses an operation evaluation system suitable for glaucoma. According to one specific embodiment, the system comprises a scanning device, a storage server, a main control chip and a display device, and the scanning device is used for scanning the eye structure of a user; the main control chip is configured to receive an eye image of a user and generate a three-dimensional eye model with a drainage valve; the main control chip is configured to obtain an initial aqueous humor flow finite element model, aqueous humor attribute information and aqueous humor inlet condition information from the storage server; the main control chip is configured to generate a finite element model to be solved according to the aqueous humor attribute information, the aqueous humor inlet condition information and the initial aqueous humor flow finite element model; the main control chip is configured to solve the finite element model to be solved; the main control chip is configured to generate operation evaluation information according to the simulation result information; and the main control chip is configured to control the display equipment to display the operation evaluation information. According to the embodiment, the safety of glaucoma treatment operation can be improved.

An ophthalmic formulation for preventing and treating cataracts contains an active substance for treating eye diseases and a pharmaceutically acceptable carrier or excipient. The active substance is oxidized cholesterol, including lanosterol or 25-hydroxycholesterol; the pharmaceutically acceptable carrier or excipient contains a surfactant, a tackifier, a cosolvent, and a solvent; the content of the oxidized cholesterol in the formulation is 0.01-5 mg / mL; and the mass ratio of the surfactant, the tackifier, the cosolvent, and the oxidized cholesterol is (1-300):(1-100):(100-3000):1, with the balance being the solvent. Upon eye drop administration, the formulation can cause the active substance to be selectively enriched in the lens of a laboratory animal to accurately exert the effect of treating cataracts. The active substance is not distributed in the aqueous humor and the vitreous body, thereby avoiding toxic and side effects on other eye tissue and the whole body.

The invention belongs to the technical field of medicines, and discloses an application of a Necrosulfenamide (NSA) compound in preparation of a medicine for resisting glaucoma trabecular network fibrosis. The NSA can inhibit abnormal activation of necroptosis-related pathways and significantly down-regulate fibrosis key factors, so that the structure and function of trabecular meshwork tissues are improved, and the aqueous humor outflow capacity is recovered. It is found for the first time that NSA not only has a stable and lasting intraocular pressure lowering effect, but also can reduce retinal ganglion cell damage in an intraocular hypertension state, and has definite treatment and protection effects on non-acute glaucoma and intraocular hypertension. The regulation effect of NSA on trabecular meshwork fibrosis is not disclosed in the prior art, the research blank in the field is filled, and a new pharmacological target and a clinical application strategy are provided for prevention and treatment of glaucoma and related intraocular hypertension diseases.

The invention discloses an eye implant which comprises an implant body, the implant body is in a strip shape, the outer contour of the upper surface of the implant body is in a protruding arch shape or a semi-arch shape and used for making contact with a sclera, and the lower surface of the implant body is in a plane shape and used for making contact with a choroid; a longitudinal drainage groove is formed in the upper surface of the implant body in the front-back direction of the implant body. The whole implant body is of a structure that the front end and the rear end are gradually thin and the middle is thick or the rear end is gradually thin and the middle is thick to the front end, the implant body can smoothly enter the suprachoroidal space, an originally narrow gap of the suprachoroidal space is expanded, the outflow amount of aqueous humor from the suprachoroidal space is increased through the longitudinal drainage grooves, the drainage effect is good, blocking is not prone to occurring, and the application range is wide. The effect of reducing the intraocular pressure is achieved. The lower surface of the implant body is planar, so that the attachment area of the implant body and the choroid is larger, the implant body can be stably attached to the choroid, the risk of displacement of the anterior chamber and the choroid is reduced, the implant body is prevented from being exposed to the anterior chamber to touch the cornea, and the risk of loss of corneal endothelial cells is reduced to the maximum extent.

Described here are systems and methods for accessing Schlemm's canal and for delivering an ocular device, tool, or fluid composition therein. The ocular devices may maintain the patency of Schlemm's canal without substantially interfering with transmural fluid flow across the canal. The fluid composition may be a viscoelastic fluid that is delivered into the canal to facilitate drainage of aqueous humor by disrupting the canal and surrounding trabeculocanalicular tissues. Some systems described here may be configured to cut or tear the trabecular meshwork with the body of an elongate member located within Schlemm's canal. Other tools for disrupting these tissues and minimally invasive methods for treating medical conditions associated with elevated intraocular pressure, including glaucoma, are also described.

Described herein are devices used to treat high intraocular pressure and glaucoma. An example device includes a plate comprising a first surface opposite a second surface. The first surface includes a series of fluid channels. The device also includes a first coating on the first surface and a second coating on the second surface. The device is configured to lower intraocular pressure by draining aqueous humor from an anterior chamber to subconjunctival space of a patient's eye.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

The utility model provides a glaucoma drainage device, and relates to the technical field of medical instruments. The glaucoma drainage device comprises a base body, a first hydrophilic layer and a second hydrophilic layer, the base body is provided with a channel penetrating through the base body in the first preset direction. The base body is provided with a first end face and a second end face which are oppositely arranged in the first preset direction. The first hydrophilic layer covers the first end surface and the second end surface; the inner wall of the channel is at least partially covered by the second hydrophilic layer. According to the glaucoma drainage device, accumulation and adhesion of substances such as protein, cells and bacteria in aqueous humor at a channel opening and in a channel can be reduced, the blocking risk of the channel is reduced, the eye aqueous humor can be better led out, intraocular pressure is reduced, and the inflammatory response of eyes can be reduced.